Gisela Santos

Gisela Santos

Auto-generated profile, based on publicly available information

Gisela Santos

Neuron Glia Biology in Health and Disease, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
ABAndreia Barateiro
Andreia Barateiro
VAVera Afonso
Vera Afonso
GSGisela Santos
Gisela Santos
JCJoao Jose Cerqueira
Joao Jose Cerqueira
Dora BritesDora Brites
Dora Brites
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes

1 February 2018 in Neuropharmacology
Verified
Journal Article
Closed access
GSGisela Santos
Gisela Santos
ABAndreia Barateiro
Andreia Barateiro
Cláudio M. GomesCláudio M. Gomes
Cláudio M. Gomes
Dora BritesDora Brites
Dora Brites
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes

11 October 2016 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
RPRui Pinheiro
Rui Pinheiro
CBCláudia Braga
Cláudia Braga
GSGisela Santos
Gisela Santos
MBMaria Bronze
Maria Bronze
MPMaria Jesus Perry
Maria Jesus Perry
AFAna Sofia Falcão
Ana Sofia Falcão

4 September 2020 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
GSGisela Santos
Gisela Santos
ABAndreia Barateiro
Andreia Barateiro
Dora BritesDora Brites
Dora Brites
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
Increased expression of S100B and its specific receptor for advanced glycation end products (RAGE) has been described in patients with multiple sclerosis (MS), being associated with an active demyelinating process. We previously showed that a direct neutralization of S100B reduces lysophosphatidylcholine (LPC)-induced demyelination and inflammation using an ex vivo demyelinating model. However, whether S100B actions occur through RAGE and how oligodendrogenesis and remyelination are affected are not clarified. To evaluate the role of the S100B–RAGE axis in the course of a demyelinating insult, organotypic cerebellar slice cultures (OCSC) were demyelinated with LPC in the presence or absence of RAGE antagonist FPS-ZM1. Then, we explored the effects of the S100B–RAGE axis inhibition on glia reactivity and inflammation, myelination and neuronal integrity, and on oligodendrogenesis and remyelination. In the present study, we confirmed that LPC-induced demyelination increased S100B and RAGE expression, while RAGE antagonist FPS-ZM1 markedly reduced their content and altered RAGE cellular localization. Furthermore, FPS-ZM1 prevented LPC-induced microgliosis and astrogliosis, as well as NF-κB activation and pro-inflammatory cytokine gene expression. In addition, RAGE antagonist reduced LPC-induced demyelination having a beneficial effect on axonal and synaptic protein preservation. We have also observed that RAGE engagement is needed for LPC-induced oligodendrocyte (OL) maturation arrest and loss of mature myelinating OL, with these phenomena being prevented by FPS-ZM1. Our data suggest that increased levels of mature OL in the presence of FPS-ZM1 are related to increased expression of microRNAs (miRs) associated with OL differentiation and remyelination, such as miR-23a, miR-219a, and miR-338, which are defective upon LPC incubation. Finally, our electron microscopy data show that inhibition of the S100B–RAGE axis prevents axonal damage and myelin loss, in parallel with enhanced functional remyelination, as observed by the presence of thinner myelin sheaths when compared with Control. Overall, our data implicate the S100B–RAGE axis in the extent of myelin and neuronal damage, as well as in the inflammatory response that follows a demyelinating insult. Thus, prevention of RAGE engagement may represent a novel strategy for promoting not only inflammatory reduction but also neuronal and myelin preservation and/or remyelination, improving recovery in a demyelinating condition as MS.

1 March 2020 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
SNSofia Pereira Das Neves
Sofia Pereira Das Neves
GSGisela Santos
Gisela Santos
CBCatarina Barros
Catarina Barros
DPDiana Rodrigues Pereira
Diana Rodrigues Pereira
RFRicardo Ferreira
Ricardo Ferreira
JCJoao Jose Cerqueira
Joao Jose Cerqueira

9 July 2014 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
ETEma F. Torrado
Ema F. Torrado
CGCátia Gomes
Cátia Gomes
GSGisela Santos
Gisela Santos
Adelaide FernandesAdelaide Fernandes
Adelaide Fernandes
Dora BritesDora Brites
Dora Brites
AFAna Sofia Falcão
Ana Sofia Falcão